Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT
- PMID: 23503574
- DOI: 10.1007/s00259-013-2372-4
Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT
Abstract
Purpose: To determine the value of combined (18)F-FDG PET/CT with diagnostic contrast-enhanced CT (CECT) in detecting primary malignancies and metastases in patients with paraneoplastic neurological syndromes (PNS) and to compare this with CECT alone.
Methods: PET/CT scans from 66 patients with PNS were retrospectively evaluated. Two blinded readers initially reviewed the CECT portion of each PET/CT scan. In a second session 3 months later, the readers analysed the combined PET/CT scans. Findings on each study were assessed using a four-point-scale (1 normal/benign; 2 inconclusive, further diagnostic work-up may be necessary; 3 malignant; 4 inflammatory). Sensitivity and specificity for malignant findings were calculated for PET/CT and CECT. Interreader agreement was determined by calculating Cohen's kappa. Pooled data from clinical follow-up (including histopathology and follow-up imaging, median follow-up 20.0 months) served as the reference gold standard.
Results: Both readers classified 12 findings in ten patients (15%) as malignant on the PET/CT scans (two patients had two primary tumours). One such imaging finding (suspected thymic cancer) was false-positive (i.e. benign histology). The most common tumours were bronchial carcinoma (n = 3), lymph node metastases of gynaecological tumours (n = 3) and tonsillar carcinoma (n = 2). Three of 12 findings (25%) were not detected by CECT alone (cervical carcinoma, lymph node metastasis and tonsillar carcinoma). In a per-patient analysis, sensitivity and specificity for malignant findings were 100% and 90% for PET/CT and 78% and 88% for CECT. In 24% (reader 1) and 21% (reader 2) of the patients, the PET/CT findings were inconclusive. Of these findings, 57% (reader 1) and 56% (reader 2) were only diagnosed with PET (e.g. focal FDG uptake of the thyroid, gastrointestinal tract and ovaries). On follow-up, none of these findings corresponded to malignancy. Overall agreement between the two readers was excellent with a Cohen's kappa of 0.95 ± 0.04 (p < 0.001) for PET/CT and 0.97 ± 0.03 (p < 0.001) for CECT alone.
Conclusion: In this cohort of patients with PNS, PET/CT exhibited improved detection of underlying malignancy versus CECT alone. While hybrid imaging produces a greater number of inconclusive findings, sensitivity is increased for the detection of head and neck and gynaecological malignancies as well as metastatic lymph node involvement.
Similar articles
-
FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.Eur Radiol. 2016 Apr;26(4):1018-30. doi: 10.1007/s00330-015-3902-1. Epub 2015 Jul 19. Eur Radiol. 2016. PMID: 26188656
-
The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.Laryngoscope. 2015 Aug;125(8):1861-8. doi: 10.1002/lary.25326. Epub 2015 Apr 17. Laryngoscope. 2015. PMID: 25892275
-
PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.Eur J Nucl Med Mol Imaging. 2011 May;38(5):822-31. doi: 10.1007/s00259-010-1702-z. Epub 2011 Jan 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21210112
-
18 F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.Curr Oncol. 2019 Aug;26(4):e458-e465. doi: 10.3747/co.26.4583. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548813 Free PMC article.
-
Diagnostic performance of various imaging modalities in localizing ectopic ACTH syndrome: A systematic review.Ann Endocrinol (Paris). 2024 Dec;85(6):596-603. doi: 10.1016/j.ando.2024.07.001. Epub 2024 Jul 11. Ann Endocrinol (Paris). 2024. PMID: 39002895
Cited by
-
Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.Oncologist. 2016 Sep;21(9):1079-84. doi: 10.1634/theoncologist.2015-0364. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401896 Free PMC article.
-
Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.Clin Transl Oncol. 2017 Jan;19(1):111-118. doi: 10.1007/s12094-016-1511-3. Epub 2016 May 2. Clin Transl Oncol. 2017. PMID: 27139696
-
[Radiological diagnostics in CUP syndrome].Radiologe. 2014 Feb;54(2):117-23. doi: 10.1007/s00117-013-2547-9. Radiologe. 2014. PMID: 24500247 German.
-
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2056-63. doi: 10.1007/s00259-015-3126-2. Epub 2015 Jul 21. Eur J Nucl Med Mol Imaging. 2015. PMID: 26194717
-
Diagnostic Value of Positron Emission Tomography Combined with Computed Tomography for Evaluating Critically Ill Neurological Patients.Front Neurol. 2017 Feb 14;8:33. doi: 10.3389/fneur.2017.00033. eCollection 2017. Front Neurol. 2017. PMID: 28261149 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical